ClinicalTrials.gg
CompletedNCT00820885Updated May 25, 2021

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

A Phase 1 interventional study of teduglutide and teduglutide in Pharmacokinetics and Safety of Elevated Doses, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Sep 2006, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study was to study the safety and tolerability of teduglutide following a once or possibly twice daily subcutaneous injection for eight consecutive days in healthy subjects. A secondary objective was to study the pharmacokinetics of teduglutide following a once or possibly twice daily injection for eight consecutive days in healthy subjects.

Read the detailed description

Healthy subjects are enrolled once they have been screened and it is determined they qualify. The subjects are randomized to either placebo or the dose of teduglutide as outlined by the protocol at a 1:3 ratio. They will be injected with investigational product for eight consecutive days, with measurements taken including safety.

02

Conditions studied

  • Pharmacokinetics and Safety of Elevated Doses
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women between 20 and 55 years of age
  • of 18-35 inclusive
  • Able to understand and sign form
  • Willing and able to be confined at the clinical research center 8.5 days
  • Women who are , surgically sterilized, or agree to use effective form of
  • Women of child bearing potential with a negative pregnancy test at screening and check-in
  • Medically healthy with normal clinical results and /lab profiles at screening and check-in

Exclusion criteria

Exclusion Criteria

  • Donated 1 pint or more of blood/blood products within 56 days prior to study or received plasma within 7 days prior to study
  • Pregnancy or become pregnant
  • Participated in another trial 30 days prior
  • Physical examination/medical history indicates clinical condition or concurrent illness unsuitable for study
  • History/presence of clincally significant disease of any body system
  • History/evidence of congenital hon-hemolytic hyperbilirubinemia
  • History/evidence of gall stone disease, stomach or intestinal surgery
  • History/evidence of colorectal cancer
  • History/evidence of GI disease, e.g., malabsorption, Crohn's Disease, etc.
  • History/evidence of skin rashes or dermatitis
  • Taking prescription or over the counter medication (with the exception of oral ) during the 7 days preceding confinement to the clinical unit
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Other
    cohort A

    20 mg dose 20 mg/ML concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort AR

    20 mg in 50 mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort C

    25 mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort D

    15 mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort E

    10 mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort F

    30mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    Cohort H

    50mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

  • Other
    cohort I

    80mg in 50mg/ml concentration and placebo

    Drug: teduglutide · Drug: tedguglutide

Interventions

  • subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

    Also known as: Gattex is the brand name

  • Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

    Also known as: Gattex

  • lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

    Also known as: Gattex

06

What researchers measure

Primary outcomes

  1. Each dose arm is safe

    Time frame: Within 1 week of each cohort completion

07

Study locations

1 site
  • Northwest Kinetics
    Tacoma, Washington 98418, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2006 to primary completion in Apr 2007, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2009
First posted
Jan 12, 2009
StartActual
Sep 6, 2006
Primary completionActual
Apr 23, 2007
CompletionActual
Apr 23, 2007
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00820885
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 12, 2009
Start date
Sep 6, 2006
Primary completion
Apr 23, 2007
Completion
Apr 23, 2007
Last update
May 25, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion